Skip to main content
Premium Trial:

Request an Annual Quote

Genomatica Awarded Phase II SBIR for Cellular Simulation Technology

NEW YORK, Nov. 4 (GenomeWeb News) - Computational systems biology startup Genomatica has received a two-year, $765,000 Phase II Small Business Innovation Research grant from the National Human Genome Research Institute to support development of its cellular simulation technology platform.

The company said it would use the award to integrate high-throughput experimental data, such as gene expression information, with its computer models of cellular metabolism.

Christophe Schilling, CTO of Genomatica and principal investigator for the grant, said that under the first phase of the SBIR, the company demonstrated the use of its models of cellular metabolism to predict gene expression patterns in yeast. The Phase II effort will illustrate "the use of computational metabolic models for the visualization, analysis, and integration of gene expression data," he said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.